- Home
- ARVN vs SMBK Comparison
ARVN vs SMBK Comparison
Compare ARVN & SMBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- SMBK
- Stock Information
- Founded
- ARVN 2015
- SMBK N/A
- Country
- ARVN United States
- SMBK United States
- Employees
- ARVN N/A
- SMBK N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- SMBK Major Banks
- Sector
- ARVN Health Care
- SMBK Finance
- Exchange
- ARVN Nasdaq
- SMBK Nasdaq
- Market Cap
- ARVN 676.2M
- SMBK 608.1M
- IPO Year
- ARVN 2018
- SMBK N/A
- Fundamental
- Price
- ARVN $10.59
- SMBK $35.92
- Analyst Decision
- ARVN Buy
- SMBK Buy
- Analyst Count
- ARVN 23
- SMBK 4
- Target Price
- ARVN $17.80
- SMBK $38.63
- AVG Volume (30 Days)
- ARVN 2.3M
- SMBK 61.7K
- Earning Date
- ARVN 11-05-2025
- SMBK 10-21-2025
- Dividend Yield
- ARVN N/A
- SMBK 0.89%
- EPS Growth
- ARVN N/A
- SMBK 41.99
- EPS
- ARVN N/A
- SMBK 2.74
- Revenue
- ARVN $312,300,000.00
- SMBK $188,204,000.00
- Revenue This Year
- ARVN N/A
- SMBK $22.13
- Revenue Next Year
- ARVN N/A
- SMBK $10.21
- P/E Ratio
- ARVN N/A
- SMBK $13.14
- Revenue Growth
- ARVN 93.86
- SMBK 18.22
- 52 Week Low
- ARVN $5.90
- SMBK $26.31
- 52 Week High
- ARVN $27.00
- SMBK $37.92
- Technical
- Relative Strength Index (RSI)
- ARVN 59.44
- SMBK 55.39
- Support Level
- ARVN $9.27
- SMBK $35.22
- Resistance Level
- ARVN $11.51
- SMBK $37.23
- Average True Range (ATR)
- ARVN 0.53
- SMBK 0.94
- MACD
- ARVN 0.02
- SMBK 0.10
- Stochastic Oscillator
- ARVN 59.15
- SMBK 58.17
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About SMBK SmartFinancial Inc.
SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.